Skip to Content
Merck
CN
  • Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.

Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.

The Journal of clinical investigation (2014-11-05)
Juan Manuel Torres, Rubén Martinez-Barricarte, Sonia García-Gómez, Marina S Mazariegos, Yuval Itan, Bertrand Boisson, Rita Rholvarez, Anaïs Jiménez-Reinoso, Lucia del Pino, Rebeca Rodríguez-Pena, Antonio Ferreira, Enrique Hernández-Jiménez, Victor Toledano, Carolina Cubillos-Zapata, Mariana Díaz-Almirón, Eduardo López-Collazo, José L Unzueta-Roch, Silvia Sánchez-Ramón, Jose R Regueiro, Eduardo López-Granados, Jean-Laurent Casanova, Rebeca Pérez de Diego
ABSTRACT

Heterotrimers composed of B cell CLL/lymphoma 10 (BCL10), mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and caspase recruitment domain-containing (CARD) family adaptors play a role in NF-κB activation and have been shown to be involved in both the innate and the adaptive arms of immunity in murine models. Moreover, individuals with inherited defects of MALT1, CARD9, and CARD11 present with immunological and clinical phenotypes. Here, we characterized a case of autosomal-recessive, complete BCL10 deficiency in a child with a broad immunodeficiency, including defects of both hematopoietic and nonhematopoietic immunity. The patient died at 3 years of age and was homozygous for a loss-of-expression, loss-of-function BCL10 mutation. The effect of BCL10 deficiency was dependent on the signaling pathway, and, for some pathways, the cell type affected. Despite the noted similarities to BCL10 deficiency in mice, including a deficient adaptive immune response, human BCL10 deficiency in this patient resulted in a number of specific features within cell populations. Treatment of the patient's myeloid cells with a variety of pathogen-associated molecular pattern molecules (PAMPs) elicited a normal response; however, NF-κB-mediated fibroblast functions were dramatically impaired. The results of this study indicate that inherited BCL10 deficiency should be considered in patients with combined immunodeficiency with B cell, T cell, and fibroblast defects.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Supelco
Ethanol standards 10% (v/v), 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
Glycine ethyl ester hydrochloride, 99%
Supelco
Dehydrated Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ethyl alcohol, Pure 190 proof, for molecular biology
Sigma-Aldrich
Ethanol Fixative 80% v/v, suitable for fixing solution (blood films)
USP
Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethyl alcohol, Pure 200 proof, Molecular Biology
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, meets USP testing specifications
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, meets USP testing specifications
Sigma-Aldrich
Ethanol, BioUltra, Molecular Biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Supelco
Ethanol, standard for GC
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof
Sigma-Aldrich
Ethanol, tested according to Ph. Eur.
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
6-Phosphonohexanoic acid, 97%
Sigma-Aldrich
Ethanol, puriss. p.a., absolute, ≥99.8% (GC)
Sigma-Aldrich
Ethyl alcohol, Pure, 160 proof, Excise Tax-free, Permit for use required